Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2170)

INSIDE INFORMATION
PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION PLAN BY THE COMPANY

This announcement is made by Suzhou Basecare Medical Corporation Limited (the "**Company**") in accordance with Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the "Guidelines on Application for 'Full Circulation' of Domestic Unlisted Shares of H-share Companies" 《(H股公司境內未上市股份申請"全流通"業務指引》) issued by the China Securities Regulatory Commission (the "**CSRC**") on November 14, 2019 and further amended on August 10, 2023 (the "**Guidelines**") regarding the procedures of application by companies whose H shares are listed on the Stock Exchange for circulation of domestic unlisted shares (as defined under the Guidelines) on the Stock Exchange.

In view of the Guidelines, the board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, the Board has considered and approved the proposal for the implementation of the H share full circulation, which is to convert 190,812,165 unlisted shares of the Company (the "**Unlisted Shares**") in aggregate into H shares of the Company (the "**H Shares**") (the "**H Share Full Circulation**"). Subject to obtaining all relevant approvals and/or filing (including the filing notice from the CSRC and the approval from the Stock Exchange) and complying with all applicable laws, regulations and rules, such Unlisted Shares will be converted into H Shares, and the Company will apply for the listing of and permission to deal in such H Shares on the Main Board of the Stock Exchange (the "**Conversion and Listing**").

Pursuant to the Company's articles of association, the H Share Full Circulation is not subject to further approval from the shareholders of the Company. As of the date of this announcement, the Company (i) has not completed the filing procedures with the CSRC; (ii) has not applied to the Stock Exchange for the Conversion and Listing; and (iii) has not yet finalized the details of the implementation plan for the H Share Full Circulation. The Company will make further announcements in due course regarding the progress and details of the application for the H Share Full Circulation and the Conversion and Listing.

The H Share Full Circulation and the Conversion and Listing are subject to the relevant procedures under the requirements of the CSRC, the Stock Exchange and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, May 12, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. ZHAO Ye and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.